Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study

Author:

Theiler MartinORCID,Knöpfel NicoleORCID,von der Heydt Susanne,Schwieger-Briel AgnesORCID,Luchsinger IsabelleORCID,Smith Alexandra,Kernland-Lang Kristin,Waelchli RegulaORCID,Neuhaus KathrinORCID,Kohler MalcolmORCID,Gnannt RalphORCID,Schoch Sarah F.ORCID,Weibel LisaORCID,Kurth SalomeORCID

Abstract

AbstractSleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on propranolol compared to a healthy, untreated control group. Sleep of propranolol-treated infants and controls was investigated using ankle actigraphy and a 24-h diary for 7–10 days at ages 3 and 6 months. The main outcome measures were the Number of Nighttime Awakenings and Sleep Efficiency. The main secondary outcome measures included 24-hour Total Sleep, daytime sleep behavior, and parent-rated infant sleep quality and behavioral development based on the Brief Infant Sleep Questionnaire (BISQ) and the age-appropriate Ages-and-Stages Questionnaire (ASQ), respectively. Fifty-four term-born infants were included in each cohort. No group difference in any investigated parameter was seen at age 3 months. At age 6 months, the propranolol group exhibited a decrease in Sleep Efficiency and a trend towards an increased Number of Nighttime Awakenings compared to the control group. Treated infants at 6 months also had shorter daytime waking periods. 24-hour Total Sleep was unaffected by propranolol. No negative impact of propranolol on subjective sleep quality and behavioral development was noted.Conclusion: Propranolol exerts a measurable yet mild impact on objectively assessed infants’ sleep measures. Behavioral developmental scores were unaffected. Our results support propranolol as first-line therapy for complicated infantile hemangiomas. What is Known:• Sleep disorders are frequently reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment discontinuation.• Investigations of the sleep pattern in this patient group using objective measures are lacking. What is New:• The sleep pattern of propranolol-treated infants is assessed using actigraphy and a 24-h sleep diary and compared to healthy, untreated controls.• Propranolol leads to a decreased sleep efficiency at night and an increased demand of daytime sleep, yet effects are mild overall.

Funder

Universität Zürich

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Foundation for Research in Science and the Humanities

Olga Mayenfisch Stiftung

Publisher

Springer Science and Business Media LLC

Subject

Pediatrics, Perinatology and Child Health

Reference51 articles.

1. Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, Annam A, Baker CN, Frommelt PC, Hodak A, Pate BM, Pelletier JL, Sandrock D, Weinberg ST, Whelan MA, SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS (2019) Clinical practice guideline for the management of infantile hemangiomas. Pediatrics 143:e20183475. https://doi.org/10.1542/peds.2018-3475

2. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ (2014) A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372:735–746. https://doi.org/10.1056/NEJMoa1404710

3. Langley A, Pope E (2015) Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol 172:13–23. https://doi.org/10.1111/bjd.13379

4. Xerfan EMS, Andersen ML, Facina AS, Tufik S, Tomimori J (2020) Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma. World J Pediatr 16:537–538. https://doi.org/10.1007/s12519-019-00335-2

5. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C et al (2016) Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics 138:e20160353. https://doi.org/10.1542/peds.2016-0353

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3